Clinical Trial Update: Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial comparing dalbavancin to a comparator for acute hematogenous osteomyelitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis

Drugs mentioned

• Dalbavancin (dalbavancin)

Snippet

Sponsor: Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) | Conditions: Osteomyelitis | Phase 3 | Status: WITHDRAWN